HIV:It seems that now all and one are Pulling together.

Roche's Fuzeon/PI more than halves number of patients with detectable HIV
levels

BASEL (AFX) - Roche Holding AG said new interim data on HIV treatment
Fuzeon (enfuvirtide) boosted by protease inhibitor (PI) TMC114/r shows more than
a doubling of the proportion of patients reaching undetectable levels of the
virus.
According to the Swiss drug-maker, the "Fuzeon effect" has also been seen in
other combination trials of Fuzeon and PI, including with lopinavir/r and
tipranivir/r.
This effective strategy for treatment-experienced patients of combining a
boosted PI with FUZEON has been recommended by the US Department of Health and
Human Services (DHHS) guidelines and is anticipated to revolutionise the
management of patients facing HIV resistance.


afx.zurich@afxnews.com
at/ec